Surrozen Inc.

10.00
-0.99 (-9.01%)
At close: Apr 07, 2025, 3:59 PM
9.80
-2.00%
After-hours: Apr 07, 2025, 04:00 PM EDT
-9.01%
Created with Highcharts 11.4.39 AM4 PM10 AM12 PM1 PM2 PM9.81010.2
Bid 8.7
Market Cap 32.81M
Revenue (ttm) 10.65M
Net Income (ttm) -63.56M
EPS (ttm) -21.67
PE Ratio (ttm) -0.46
Forward PE -2.67
Analyst Buy
Ask 12.61
Volume 8,926
Avg. Volume (20D) 20,200
Open 10.00
Previous Close 10.99
Day's Range 9.75 - 10.10
52-Week Range 6.00 - 18.17
Beta 0.74

About SRZN

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 11, 2021
Employees 42
Stock Exchange NASDAQ
Ticker Symbol SRZN
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for SRZN stock is "Buy." The 12-month stock price forecast is $38.5, which is an increase of 285.00% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy0213
Price Target: $38.5
(285.00% upside)
Analyst Consensus: Buy
Stock Forecasts
2 months ago
+7.29%
Surozen shares are trading higher after HC Wainwri... Unlock content with Pro Subscription
3 months ago
+19.44%
Surrozen shares are trading higher after Guggenheim upgraded the stock from Neutral to Buy.